Form 4: IGC Pharma Director Terry L. Lierman Acquires Options

Director Terry L. Lierman reports acquisition of options to purchase 150,000 shares of IGC Pharma common stock.

Summary

• Terry L. Lierman, a director of IGC Pharma, Inc., filed a Form 4 disclosing a transaction involving derivative securities.
• On March 13, 2024, Lierman acquired 150,000 options to buy shares of IGC Pharma common stock at an exercise price of $0.30.
• 50,000 of these options vest immediately, while the remaining 100,000 vest over two years starting in 2025.
• The options are exercisable in equal amounts on March 2024, 2025, and 2026, and expire on March 12, 2034.
• Following the transaction, Lierman beneficially owns 150,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of option grants to a director. While option grants can be seen as a positive incentive, this is a routine filing.

Positives

• The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency to the market regarding their transactions in the company's securities.

Stakeholder Impact

• The acquisition of options by a director may have a minor positive impact on shareholder sentiment.

Key Dates